ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » (1405–1433) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II

Date: Monday, October 27, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM
Abstract Number: 1406
A Combined Score of Facet Joint Ankylosis and Syndesmophyte Development Correlates Well with Spinal Mobility in Axial Spondyloarthritis
10:30AM-12:30PM
Abstract Number: 1405
A Combined Score of Syndesmophytes and Facet Joint Ankylosis Improves Sensitivity to Spinal Structural Damage Progression in Axial Spondyloarthritis
10:30AM-12:30PM
Abstract Number: 1420
A Nationwide Analysis of In-Hospital Mortality in Adult Ankylosing Spondylitis
10:30AM-12:30PM
Abstract Number: 1428
Ankylosing Spondylitis Related Mortality Trends in USA from 1999-2020: Analysis of CDC Wonder Database
10:30AM-12:30PM
Abstract Number: 1422
Assessment of difficulties, modifications and use of work adaptations in patients with axial spondyloarthritis: validation of the DificuLtAx and ModAL questionnaires
10:30AM-12:30PM
Abstract Number: 1412
Classification of sacroiliits using an artificial intelligence model
10:30AM-12:30PM
Abstract Number: 1417
Common Causes of Hospitalization in Spondyloarthritis Patients: A Nationwide Analysis
10:30AM-12:30PM
Abstract Number: 1411
Defining Minimal Disease Activity (MDA) in Psoriatic Arthritis (PsA) with the inclusion of Psoriatic Arthritis Impact of Disease (PsAID) scores rather than Health Assessment Questionnaire (HAQ)
10:30AM-12:30PM
Abstract Number: 1419
Effectivenss of an educational program on non-radiographic axial spondyloarthritis
10:30AM-12:30PM
Abstract Number: 1410
Examining the Interchangeability of Two Different Patient-Reported Global Assessment Measures in an Observational Axial Spondyloarthritis Cohort
10:30AM-12:30PM
Abstract Number: 1423
Genetic and Cytokine Correlates in Ankylosing Spondylitis: rs27038 polymorphism of ERAP1 gene and IL-17 Interactions : A Case-Control Study
10:30AM-12:30PM
Abstract Number: 1433
Identifying Predictors of Difficult-to-Manage Axial Spondyloarthritis: Real-World Insights from a Taiwanese Registry Cohort
10:30AM-12:30PM
Abstract Number: 1427
Impact of Biologic Therapy on Subclinical Atherosclerosis and Ventricular Function in Psoriatic Arthritis
10:30AM-12:30PM
Abstract Number: 1421
Impact of Psoriatic Arthritis Disease Activity and Fatigue on Subjective Cognitive Decline (“Brainfog”)
10:30AM-12:30PM
Abstract Number: 1418
Impact of Type 2 Diabetes Mellitus on Cardiovascular Outcomes in Patients with Ankylosing Spondylitis on NSAID Therapy
10:30AM-12:30PM
Abstract Number: 1432
Long-term Radiographic Progression in Early versus Established Axial Spondyloarthritis: A 12-Year Observational Study
10:30AM-12:30PM
Abstract Number: 1424
Mapping Central Nervous System Responses To Painful Stimuli In Patients With Axial Spondyloarthritis
10:30AM-12:30PM
Abstract Number: 1414
Multidimensional Assessment to Differentiate Early Psoriatic Arthritis from Cutaneous Psoriasis
10:30AM-12:30PM
Abstract Number: 1425
Quantifying Functional Impact of Structural Damage in Psoriatic Arthritis: Insights from a Long-Term Prospective Cohort
10:30AM-12:30PM
Abstract Number: 1431
Radiographic Sacroiliitis in Psoriatic Arthritis: Clinical, Laboratory, and Spinal Radiographic Correlates in an Indian Cohort
10:30AM-12:30PM
Abstract Number: 1430
Redefining BASDAI cut-offs: implications for patients’ eligibility for initiating biologic disease-modifying antirheumatic treatment in axial spondyloarthritis
10:30AM-12:30PM
Abstract Number: 1413
Restless Legs Syndrome in Patients with Psoriatic Arthritis: Association with Inflammatory, Clinical Parameters, and Comorbidities
10:30AM-12:30PM
Abstract Number: 1416
Structural Damage Progression in the Spine in Patients with Psoriatic Arthritis: Findings from a Longitudinal Cohort Study
10:30AM-12:30PM
Abstract Number: 1429
Survival Outcomes in Elderly Patients with Axial Spondyloarthritis and Concomitant Cancer
10:30AM-12:30PM
Abstract Number: 1415
The Association of Handedness with Radiographic Damage in Patients with Psoriatic Arthritis
10:30AM-12:30PM
Abstract Number: 1409
The impact of depression in axial spondyloarthritis: Epidemiological insights from the Ankylosing Spondylitis Registry of Ireland (ASRI)
10:30AM-12:30PM
Abstract Number: 1407
Trends in Diagnostic Timing and Clinical Features of Axial Spondyloarthritis by Sex and Clinical Subtype: A Multicenter Cohort Over Seven Decades
10:30AM-12:30PM
Abstract Number: 1426
Understanding the Drivers of BASDAI and Back Pain Scores in Psoriatic Arthritis
10:30AM-12:30PM
Abstract Number: 1408
When Damage and Disability Diverge: Unraveling Sex-Based Drivers of Axial Spondyloarthritis Burden

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology